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ABSTRACT

Ha, Soo Jung. MS, Purdue University, May, 2014. Lipidomic Analysis of
Glioblastoma Multiforme. Major Professor: Kari L. Clase.

Glioblastoma Multiforme (GBM) is the most common and malignant form of the
primary brain tumor. Due to its highly invasive nature, current treatment options
have not been able to improve the survival rate in past 20 years. In order to
discover GBM therapeutic targets, omics technologies have been widely used to
identify potential biomarkers.
This research study focused on investigating lipid biomarkers of human
GBM orthotopic mouse models employing mass spectrometry. Human tumor cell
lines GBM10 and GBM43 were injected in the right cerebral hemisphere and
flank sites in NOD/SCID mice (n = 10 mice per group). Left cerebral hemispheres
of the mouse brains were harvested as control tissue. After harvesting brain and
flank tumors and control brain from the xenograft models, protein, metabolites,
and lipids of tumor samples were collected through the simple extraction
procedure. These samples were analyzed by reverse phase high performance
liquid chromatography – Fourier transform ion cyclotron resonance mass
spectrometry (RHPLC-FTMS). FTMS analyzers have the highest resolving power
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of all MS instruments, which is ideal for complex mixtures such as GBM tissue.
Spectra obtained from the FTMS analysis were analyzed using Student t-tests to
detect significant differences in tissue profiles at a level of p = 0.05. Compounds
below this threshold were identified through a database using the m/z ratio.
Lipidomic analysis indicated the possible differentially expressed lipids
classes in GBM tissues, and connected to metabolic pathways, tumor
proliferation and immunodepression. Most significantly expressed lipids were
glycerophospholipids, glycerophosphocholines, glycerophoserines, and
triradylglycerols. Accompanying these studies is a collaborative effort to improve
the effectiveness and efficiency of computational pipelines that are imperative to
the analytics, visualization, identification, and interpretation of the omics data.
Only by carefully integrating the computational pipelines can we successfully
perform the types of integrative studies needed to advance the identification of
cancer biomarkers for diagnosis and prognosis, and our integrative studies serve
as a case study for our pipeline advancement efforts.
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CHAPTER 1. INTRODUCTION

This chapter introduces the overview of lipidomic analysis of Glioblastoma
Multiforme (GBM) research study. This chapter provides a statement of purpose
in GBM cancer studies, research questions, scope and significance of the study
that explain needs of knowledge in cancer lipids, definitions of key terms,
assumptions, limitations, and delimitations of this research study.

1.1

Statement of Purpose

Cancer has become one of the most common diseases in people’s lives.
Although many scientists attempt to find the effective way of treatment for cancer,
the success rate has not dramatically increased over the past several decades.
Glioblastoma Multiforme (GBM) is one of the most aggressive types of cancer
that occurs in the human brain. Current treatment options of glioblastoma have
not increased survival rates of GBM patients beyond 20 years. The purpose of
this research is to discover potential cancer targets of GBM by using cutting edge
technologies to investigate proteins, metabolites, and lipids of orthotopic and
subcutaneous xenograft mouse tumor tissues. Figure 1.1 overviews the general
cancer proteomics workflow and therapeutic goals using different existing models.
However, studies of proteins have not been sufficient to identify effective
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targeting biomarkers. This experiment includes analysis of metabolites and lipids
of GBM to explain distinct characteristics of GBM along with protein biomarkers.
This thesis covers the lipidomics part of the project.

Figure 1.1. Generalized workflow for cancer proteomics studies using model
systems and clinical samples (Collins et al., 2009).
Another important goal of this study is the comparison of various existing
cancer models to explain the morphology changes of cancer cells in different
microenvironment and reliability of the models. Cancer models such as human in
vitro, mouse in vivo, and naturally occurring animal cancer play critical roles in
cancer research. This research study utilized orthotopic and subcutaneous
xenograft mouse models and two different human GBM cell types (GBM10 and
GBM43) to compare and identify the lipid composition of GBM. Furthermore,
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these results were examined to discover metabolic characteristics of the GBM
that can potentially be compared with metabolite and protein data in the future.

1.2
•

Research Questions

What are the similarities and differences of molecular profiles between
brain (orthotopic) and flank (subcutaneous) tumors in mouse xenograft
model?

•

Are there biomarkers in GBM10 and GBM43 that are related to metabolic
properties of GBM?

1.3

Scope

The scope of this study was lipidomic analysis of Glioblastoma Multiforme
(GBM) using electrospray ionization Fourier transform mass spectrometry (ESIFTMS; 7 T Bruker Instrument) and various data analysis tools. The research
focused on the characterization of lipids in orthotopic and subcutaneous mouse
xenograft models using comparative analysis to investigate the characteristics of
GBM that can possibly provide evidence in the unique patterns of GBM
metabolism. Furthermore, this data explained the interactions between
metabolite and protein profiling data for future work. Global lipid profiling data
from mass spectrometry was analyzed using various bioinformatics tools
(MzMine2 and LIPID MAPS) and statistical method to identify the significant lipid
contents from the xenograft tumor samples.

4
1.4

Significance

Technology plays a significant role in disease studies, including cancer
research. Omics studies have been employed in disease studies to investigate
the characteristics of the disease and to discover novel biomarkers. According to
The Cancer Genome Atlas, more than 500 human GBM tumors have been
sequenced and characterized (Brennan et al., 2013). In addition to active
investigation of GBM genomics, whole proteome analyses were performed using
various human samples in the past decade (Niclou, Fack, & Rajcevic, 2010).
Even though genomics and proteomics provide knowledge of GBM, these
studies fail to suggest effective targets for therapy.
Lipidomics is a relatively new field, introduced in 2003 by Han and Gross
(Niclou, Fack & Rajcevic, 2010). Lipids in GBM have not been studied as much
as proteins and genomes due to biological and technical challenges. However,
lipids have many important functions in biological systems, such as energy
storage, structural components, cell membrane composition, and cell signaling.
Moreover, human brain tissue consists of five to 15% lipids, the highest amount
of lipids in comparison to other organs within the body (Campanella, 1992). Lipid
metabolism regulated by oncogenic signaling pathways is known to play an
important role in cancer initiation and progression (Zhang, 2010). However, the
role of lipids in cancer studies is still poorly understood due to biological and
technical difficulties (Shevchenko & Simons, 2010; Tripathy, 2011). As a result of
lack of lipidome information, genomic and proteomic profiles have not been
integrated with lipidomics. The majority of lipid metabolism in cancer studies
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investigate protein levels of tumor tissues in order to predict the lipid function and
composition. These studies also tend to focus on the importance of lipid
synthesis.
In order to explore discovery lipidomics, the two most common types of
xenograft mouse models were used to generate GBM tumors from human GBM
cells lines. Human GBM10 and GBM43 that were provided by Mayo Clinic,
Rochester, Minnesota, were injected into both subcutaneous (flank) and
orthotopic (intracranial) sites. Tumors from different xenograft models may
represent different histopathologic, genetic, and growth properties of GBM. From
our data, we hypothesized that fatty acid oxidation plays a critical role in
glioblastoma development and malignancy of the tumor as much as lipid
synthesis. To test this assumption, proteomic and metabolomic data will be used
to validate the metabolic patterns in GBM. This study is also a collaborative effort
to improve the effectiveness and efficiency of computational pipelines that are
imperative to the analytics, visualization, identification, and interpretation of the
omics data through integration of existing analytical algorithms. Integrative
studies serve as a case study for our pipeline advancement efforts and
identification of therapeutic biomarkers.
Integrated omics study can characterize the distinct biological properties
of GBM that can lead to effective way of targeting malignant brain tumors. This
thesis covers the lipidomic element of the project. A novel extraction method
used to collect proteins, metabolites, and lipids in a single sample preparation
resolves the challenges in biological sample preparation. ESI-FTMS allows
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different biological levels of samples to generate the global profiling data with the
highest sensitivity and mass accuracy among existing instruments. Another
important goal of this study is to compare existing models to investigate the
similarities and differences between different GBM models to improve the cancer
modeling system and justify how well these models can mimic human GBM. The
results of the study provide insights into the improvement of outcomes in the
discovery of novel GBM biomarkers and a GBM modeling system.

1.5

Definitions of Key Terms

apoptosis – a distinct process of cell death that is responsible for cell death (Kerr
& Winterford, 1994).
biomarker – molecular indicator that distinguish normal or diseased process
states in the body (Tainsky, 2009).
carcinogen – compound that causes formation of DNA adducts. It has an ability
to initiate various genetic mutations that cause cancer (Herbst et al., 2008).
lipidomics – system-level identification and quantification of pathways and
networks of cellular lipids, molecular species, and interactions (Tripathy,
2011).
mass spectrometry – the study of matter that is transformed into gas-phase ions
and detect by mass/charge ratio (Murray et al., 2013)
metabolites – small molecules that have functions in cellular state and are
chemically transformed in metabolism (Patti, Yanes, & Siuzdak, 2012).
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metabolomics – the global quantitative study of metabolites using omics
technologies that utilizes the analytical instrumentation with pattern
recognition techniques to investigate changes in metabolites (Beger,
2013).
metastasis – cancer cell detachment from the primary tumor site and migration to
other body sites through the lymphatic or blood circulatory systems
(Chiang & Massague, 2008; Gupta & Massague, 2006).
oncogene – a gene that is mutated by carcinogens and causes uncontrollable
cell growth that becomes cancer cells (Herbst et al., 2008).
proteomics – technology-driven scientific study of proteins, especially their
changes, proteomes, post-translational modifications, and interactions
(Fountoulakis, 2001).
Temozolomide (TMZ) – a DNA alkylating agent that demonstrates antitumor
activity used for glioma treatment (Stupp et al., 2005).
tumorigenesis – genetic alterations that generate the progressive transformation
of normal cells into a highly malignant tumor (Hanahan & Weinberg, 2000).
xenograft – in cancer studies, human tumor cell transplantation into
immunocompromised mice that do not reject human cells (Richmond & Su,
2008).

1.6

Assumptions

The following assumptions are inherent to the pursuit of this study:
•

In vivo tumor cells are not contaminated by microbial contaminants.
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•

Lipid profile data that is generated by mass spectrometry is accurate.

•

In vivo tumor environment can change morphology of GBM.

•

Lipid database matches theoretical mass/charge ratio of lipids from GBM.

1.7

Limitations

The following limitations are inherent to the pursuit of this study:
•

Human GBM10 and GBM43 were used to generate tumors in mouse
xenograft models and generate data.

•

Orthotopic and subcutaneous mouse xenograft tumors were used as
different cancer models.

•

MzMine2 and LIPID MAPS were used to identify the significant lipids of
GBM.

1.8

Delimitations

The following delimitations are inherent to the pursuit of this study:
•

Not all types of GBM samples were used to represent GBM results.

•

There was no comparison of results using different bioinformatics tools
other than MzMine2 and LIPID MAPS.

•

Existing cancer models other than mouse were not examined for the
comparison.
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1.9

Summary

This chapter has provided an overview of the research study, including
statement of purpose, research question, scope, significance, definitions of key
terms, assumptions, limitations, and delimitations. The next chapter provides an
overview of glioblastoma, current treatment options, proteomics, metabolomics
and lipidomics in cancer, biomarker discovery, and animal models of GBM.

10

CHAPTER 2. REVIEW OF RELEVANT LITERATURE

Glioblastoma (GBM) is known as an aggressive form of brain tumor that
has a low survival rate. This chapter provides an overview of glioblastoma,
current treatment options, and research focus. It introduces current and future
treatment options of GBM and optimization of animal models to understand the
characteristics of human GBM. Characteristics of omics studies are also
discussed.

2.1

Glioblastoma Multiforme

Glioblastoma Multiforme (GBM) is the most common form of primary brain
tumor (Pelloski & Gilbert, 2007). GBM is also called a grade IV astrocytoma
(Kleihues, Burder, & Scheithauer, 1993). GBM represents about 50% of all
gliomas and is a distinct primary tumor type (Jellinger, 1978). Figure 2.1 shows
the distributions of primary brain and CNS tumors (figure 2.1 A) and primary
brain gliomas in the United states from 2004 to 2006 (figure 2.1 B). Despite many
treatment options, it is still incurable and has less than a two-year survival period
from the time of diagnosis. GBM can occur at all ages and most frequently in the
elderly (Ohgaki et al., 2004). Progression of gliomas shows genetic and
epigenetic alterations, including the loss of tumor suppressor gene function
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(PTEN, TP53, INK4A/p16, ARF/p19, Rb) or activation of oncogentic pathways
(p21-Ras, PI3-kinase, EGFR, CDK4, MDM2) (Agnihotri et al., 2013).

Figure 2.1. Primary brain tumor distributions (Agnihotri et al, 2013).
Glioblastoma Multiforme is highly invasive and malignant and the tumor
cells migrate great distances from the primary tumor site by its diffuse infiltration
characteristic. Tumor cells disseminate from the primary tumor site and migrate
along the white matter tracks, the basal lamina of brain blood vessels, or in
between the glia limitans and the pia matter. Invasion of GBM steps include
sequential adhesion to the extra cellular matrix (ECM) using CD44 and
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hyaluronan-mediated motility receptor (HMMR), degradation of the ECM, and
altered cell contractility and motility (Agnihotri et al., 2013).

2.2

Treatment Options in Glioblastoma

Prognosis of Glioblastoma (GBM) have not been changed over several
decades even though diagnostic modalities, surgical techniques, and adjuvant
treatment strategies have been developed dramatically in the last 30 years
(Oertel, von Buttlar, Schroeder, & Gaab, 2005) . GBM has a median survival time
of approximately 12 to 15 months from diagnosis. The two-year survival rate is
only about five to 15% (Stupp et al., 2005). Due to the extremely aggressive
nature of GBM, current treatment options are not designed to improve patients’
quality of life, but simply to extend their life (Lipsitz et al., 2003). There are
several treatment options for glioma treatment.

2.2.1 Current Therapies
Surgery may eliminate some tumor tissue using maximal resection and
intra-operative resection (local treatment) (Pelloski & Gilbert, 2007). The study
shows that surgery may extend survival times approximately 14 weeks. However,
GBM surgery is very difficult because of GBM’s invasive, diffuse, and poorly
defined borders of the tumor (Agnihotri et al., 2013). Autopsy studies show that
malignant cells are found in brain distant from the primary site (Pelloski & Gilbert,
2007). GMB is incurable by surgery in the majority of patients due to more than
80% of recurrence rate within the original tumor site. However, the surgical
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method is important for managing the tumor in patients. Radiotherapy and
chemotherapy are usually administered after surgery to increase survival rate of
GBM patients (Reardon & Wen, 2006).
Due to difficulties of design and implementation, only a few prospective
surgical trials have been attempted. A surgical design utilizing 5-aminolevulinic
acid has been recently attempted in Germany. This method uses 5aminolevulinic acid in order to help surgeons perform maximized resection of
contrast-enhancing portion of GBM (Pichlmeier et al., 2008). However, current
surgical methods have not increased patients’ overall survival period dramatically.
Radiation is broadly used to decrease the GBM tumor site in the brain and
slow the process of cancer and it is commonly coupled with the surgery method.
However, GBM is difficult to treat with radiation due to GBM’s tendency to widely
infiltrate brain tissues. (Pelloski & Gilbert, 2007). No perspective radiation studies
have been attempted and existing techniques, intensity-modulated RT (IMRT)
and traditional 3-dimensional EBRT, have not shown improved results in GBM
therapy (Clarke et al., 2010).
Another brain tumor therapy that is used most commonly is chemotherapy.
Temozolomide (TMZ) is the most widely used GBM chemotherapy drug that has
great oral bioavailability, no significant drug-drug interactions, and no cumulative
myelotoxity. This chemotherapeutic agent has a potential to improve overall
survival in human GBM patients. TMZ increased the long-term survival rate from
10.4 to 26.5%.
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Investigation of TMZ combination with other cytotoxic chemotherapies and
with cytostatic agents may increase survival period. However, resistance of
GBM to chemotherapy is common (Reardon & Wen, 2006).

2.2.2 Advances in Therapies
Despite these treatment options, recurrent glioblastoma patients gain only
minimal or modest improvement from current treatments. The objectives of GBM
therapy investigation are to target cellular pathways or specific biomarkers in
pathogenesis and to identify molecular properties of cancer that predict a
therapeutic response. On-going GBM research focuses on inhibition of tumor
function, survival, proliferation, apoptosis, invasion, and angionesis (Agnihotri et
al., 2013). Much current research investigates the neural signaling pathway of
glioblastoma to block tumor growth. Knowledge of signaling pathways has
elucidated new potential therapeutic targets. A large number of new glioblastoma
drugs target these signaling pathways. Since proliferation and survival pathways
are mostly regulated by growth factors and their receptors, inhibition of these
pathways and receptors can eliminate and prevent tumor formation in brain.
There are also many studies to inhibit angiogenesis of tumors, Ras/MAPK and
PI3K/Akt pathways, proteasomes, and histone deacetylases (Reardon & Wen,
2006).
Another advance in the treatment of glioblastoma is an antiangiogenic
therapy. The formation of new blood vessels, angiogenesis, plays an important
role in tumor growth. Tumor growth and spread are sustained by oxygen,
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nutrients, and growth factors through blood vessels (Hamahan & Folkman, 1997).
In malignant gliomas, angiogenesis is associated with an increase in vascular
endothelial growth factor (VEGF). VEGF is a protein that promotes formation of
new blood vessels, which stimulates endothelial cell growth, migration, and
survival from preexisting blood vessels (Hicklin & Ellis, 2005). There are several
drugs that are on trial for malignant gliomas. Bevacizumab is a monoclonal antiVEGF antibody that is in several phase 2 trials. However, Bevacizumab has
serious toxicity that could promote a more invasive aggressive tumor and shorten
survival period (Stupp et al., 2009). Cilengitide is an inhibitor of αvβ3 and αvβ5
integrin receptors, which are activated by VEGF and promote angiogenesis
(Meredith et al., 1993). It has been investigated in phase 2 trials with and without
radiation/Temozolomide on recurrent GBM (Stupp et al., 2007). Another drug that
is in trial for antiangiogenesis is Talampanel. Talampanel is a glutamate receptor
blocker that inhibits the proliferation and migration of GBM. It showed statistically
significant improvement in GBM patients and will be investigated in a phase 3
trial (Grossman et al., 2009).
A variety of other cancer therapeutic approaches are under active
investigation. Gene therapy uses the insertion or modification of genes into a cell
to treat cancer. Gene delivery can be performed using vectors from viruses or
synthetic vectors such as nanoparticles. However, clinical trials have been limited
due to a short distance of the delivery site (Clarke, et al., 2010).
Immunotherapeutic therapy has been studied for glioma. There are two
types of immunotherapy: active immunotherapy and passive immunotherapy.
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The goal of active immunotherapy is to promote long-term immune responses by
up-regulating immunity against the tumor. Long-term immunity could potentially
prevent future tumor recurrence (Clarke, et al., 2010). Tumor vaccines such as
EGFRvIII and dendritic cells are in trial to improve GBM treatment (Luptrawan et
al., 2008; Choi et al., 2009). Passive immunotherapy attempts to achieve an
immediate effect of immune response for short-term immunity by transferring
immune effectors. Antibody-mediated drug delivery has been used to increase
the local drug concentration and minimize nonspecific systemic exposure
(Mitchell & Sampson, 2009). Although there are various approaches of GBM
treatment, many treatment options are still in trials and they have not led to a
significant increase in the survival period of GBM patients.

2.3

Animal Models of Glioblastoma

Proteomic studies using clinically relevant model systems have potential
to discover novel cancer target molecules. Cancer models are investigated to
understand disease progression, tumor adaption, and treatment responses.
Animal models help researchers to design more controlled experiments,
including reproducible sampling, duplicable experiments, and tumor progression
over different time periods. Although models have several advantages in clinical
research, few glioma studies analyzed animal models (Niclou, Fack, & Rajcevic,
2010).
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2.3.1 Current Animal Models
Human/rat xenograft glioblastoma models are commonly used to identify
the protein expression in highly malignant, non-angiogenic brain tumors (Niclou,
Fack, & Rajcevic, 2010). Figure 2.2 shows the types of mouse models in cancer
research, advantages, and disadvantages among different mouse models. The
features of ideal GBM models should include good representation of human
GBM, gene, and metabolism alteration, reproducibility, and similar tumor
progression progress (Yi, Hua, & Lin, 2011). These models are also required to
mimic physiological tumor traits, including tumor invasive growth,
neovascularization, necrosis, and psedopalisading cells (Miura et al., 2010).

Figure 2.2. Types of cancer mouse models (Richmond & Su, 2008).
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Current GBM mouse models are highly efficient for tumor formation, appropriate
tumor growth rate, and an accurate tumor growth site. Although mouse models
have been playing important role in GBM research for over 30 years, these
models have had limitations in providing important biological and pathological
properties of human GBM ( Yi, Hua, & Lin, 2011). The xenograft tumor models
lose genomic and phenotypic properties of human tumor (Martens et al., 2008;
Sausville and Burger, 2006; Taillandier et al., 2003). In the result, these models
does not represent GBM heterogeneity (Bonavia et al., 2011; Lee et al., 2006;
Verhaak et al., 2010).
Rats and rodents are good models to understand human cancer as they
are cost effective and time efficient (Pang & Argyle, 2009). However, rat models
have not been effective to improve human GBM treatment due to the
physiological differences between humans and rats. Successful treatment from
rodents often does not translate into the same success in human patients (Pang
& Argyle, 2009). Mice models show similar results as rat models. Many drugs
that are effective treatments for mice show low success rates in human clinical
trials due to low efficiency or toxicity to human patients.
In this research two different xenograft tumors, flank tumors and brain
tumors, were used to discover potential biomarkers, identify distinct patterns of
metabolites and lipids of GBM, and to explore the similarities and differences of
mouse tumors and human GBM. Flank tumors usually have excessive tumor
growth and low immune response on the tumor site (Speroni et al., 2009). Flank
tumor also does not represent invasive growth of tumor (Yi, Hua, & Lin, 2011).
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Orthotopic tumors have higher cellular influx and higher local immune response.
Compared to flank tumors, orthotopic tumors are smaller and have shorter
survival rates. These tumors are also highly vascularized (Speroni et al., 2009).
Although orthotopic models provide metastatic properties, they often fail to
represent the traits of human GBM invasion, diffuse infiltration of the cells, and
gene alternations (Speroni et al., 2009; Yi, Hua, & Lin, 2011).

2.3.2 Naturally Occurring Cancer Animal Models
Using spontaneous mammary cancers of other species would be suitable
as a better model than rodents for human cancer and enhance understanding of
human carcinogenesis (Cocola et al., 2009). Naturally occurring cancers in dogs
or cats can be suitable models for study of human glioblastoma on several
different levels. Cancer in dogs and humans shares strong anatomical and
physiological similarities, including histological appearance, tumor genetics,
molecular targets, biological behavior, and response to therapies. Cancerassociated genetic mutations that promote cancer progression in humans have
been found in canines. Canine and human cancers also share initiation and
progression factors, including age, nutrition, gender, reproductive status, and
environmental exposures. Due to the physiological similarities between dogs and
humans, several human chemotherapy treatments have been used in veterinary
medicine as cancer treatment. According to interrogation of the genome
sequence, approximately 19,000 canine genes match to similar or orthologous
genes in humans. Several important human cancer-related genetic mutations
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and molecular signaling pathways have been identified in canine cancers
(Paoloni & Khanna, 2007).
Canine models are able to generate mammospheres and tumourspheres.
These models have the capacity to be long-term non-adherent cultures and
generate more complex structures. Canine models also allow for the propagation
and enrichment of cancer stem-like cells (Pang & Argyle, 2009). The goal of
studying spontaneous cancer models is to compare for gene identification,
discover environmental risk factors, understand tumor formation and progression,
and develop new therapies (Argyle & Khanna, 2006). Accommodation of canine
GBM models for new drug studies may improve human cancer trials to discover
new cancer drugs.
Naturally occurring canine cancer models are necessary to demonstrate
the targeting specificity of cancer treatment within a naturally heterogeneous
tumor environment. Naturally occurring canine models can provide the ability to
evaluate the potential toxicities and efficacy of this drug and find novel cancer
treatment (Paoloni & Khanna, 2007).

2.4

Proteomics

Proteomics is technology-driven scientific study of proteins, especially
their changes, proteomes, post-translational modifications, and interactions
(Fountoulakis, 2001). Proteomics focuses on investigating the structure and
function of the proteins of the human genome, including the delineation of
signaling networks and the regulation of the cell function (Khalil, 2006). There are
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approximately 35,000 genes in the human genome and theoretically 500,000 to
1,000,000 proteins can be translated (Galvao et al., 2011).
Proteomics plays an important role in characterizing cancer addition to
genomics. Since genomics does not directly translate to proteins, mRNA
expression data alone is insufficient to predict cellular functions. Addition of
proteomic data provides access to a global view of molecular changes in different
stage of diseases. Many disease studies attempt to understand changes in
protein levels of functions to improve and discover new treatment options.
Existing drug mechanisms focus on inhibiting the disease-related protein
activities (Khalil, 2006).
Proteomics research focuses on two strategies. The first strategy of
proteomics is to define protein-protein interactions in order to investigate complex
networks of intracellular signaling pathways. The second strategy is to monitor
large-scale global expression of different proteins and quantitatively identify the
changes of expression patterns (Simpson & Dorow, 2001). Investigations of
global protein expression are conducted in disease studies to identify biomarkers
for diagnosis, prognosis, and for identification of therapeutic targets, especially in
cancer research.

2.4.1 Cancer Proteomics
Proteomic approaches are widely used in cancer studies. The goal of
proteomic analysis in cancer research is to identify new biomarkers for diagnosis
and classification of cancer and for defining targets for more-effective therapeutic
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outcomes (Simpson & Dorow, 2001). Moreover, discovering pathways of cellular
signaling networks has a potential to eliminate tumor initiation and progression
(Collins, 2009).
Cancer proteomics mainly investigates increased proto-oncogene
expression, inactivation of tumor suppressor genes, chromosomal instability,
alterations in DNA repair genes, telomerase reactivation, structural proteins,
signal-transducers, cell-cycle regulators, and epigenetic alterations that result in
disregulation of cell proliferation, clonal selection, and tumor formation (Galvao et
al., 2011; Rodenhiser & Mann, 2006). Quantitative value of protein expression in
a proteome provides the information on the cell response due to changes in its
cellular environment. The results of these changes are up- regulated or downregulated proteins, which may regulate cellular activities related to tumor initiation,
progression, and metastasis (Khalil, 2006). Information about oncogenic and
tumor suppressor proteins and growth factor receptor signaling pathways has
been provided through proteomics. Proteomics-driven cancer research has the
potential to define protein-protein interaction networks that lead to tumor
deregulation and inhibition of cancer progression (Collins, 2009).

2.4.2 Cancer Biomarkers
Biomarkers are molecular indicator of a biological status. Biomarkers can
be detected in the blood, body fluids, or tissues. Discovery of biomarkers in
cancer is important for several reasons: early detection of cancer, diagnosis,
prognosis, response to therapy options, and cancer recurrence. It also improves
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decision making for appropriate patient treatment. Tumor biomarkers express
cancer-specific mutations, or changes in gene expression or promoter
methylation. These changes can result in alterations in protein expression.
Cancer-specific protein alterations can be expressed in the protein abundance or
the modification of post-translational proteins (Tainsky, 2009). The concentration
of specific biomarkers is highest in the tumor cells and its microenvironment
(Hondermarck, 2003; Simpson et al., 2008) and combination of several different
markers affect tumor behavior (Alaiya et al., 2000).
There are three main useful markers in cancer: diagnostic, prognostic, and
predictive markers. These markers provide tumor information about the
malignant potential and the prognosis. Diagnostic markers are used to help
histopathological classification. Prognostic markers include hormone receptors,
proliferation markers, proteases, and angiogenesis markers. These markers are
used in diagnosis of cancer. Predictive markers are used to decide different
therapy options (Alaiya et al., 2000).
Proteome analysis of glioma has been attempted in different models such
as human patients’ biopsies and body fluids, human glioma in vitro cell lines, and
animal models to discover new treatment targets. Proteins that were discovered
to be significantly up-regulated due to brain tumor grade include GFAP, IGFbinding protein 2 (IGFBP2), IGFBPS, PBEF1/NAmPRTase (Nicotinamide
phosphoribosyltransferase, plasminogen activator inhibitor-1 (PAI -1), CathepsinD, YKL-40, MMP9 and low MW Caldesmon (1-CaD). According to the literature,
the GBM pathways that are disrupted are the Ras/MAPK, the PI3K/Akt, the
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retinoblastoma and the p53 pathways (Niclou, Fack, & Rajcevic, 2010).
Identification and characterization of protein expression changes in the cells have
potential to discovery the target biomarkers of cancer (Tainsky, 2009).

2.4.3 Limitations
Proteomics already plays a huge role in studies of mechanisms of tumor
formation and identification of proteins for cancer diagnosis and treatment targets
(Collins, 2009). However, there are still challenges due to several reasons. There
are two major limitations on the cancer biomarker discovery. First, diverse
populations of human samples that are collected under various clinical conditions
are required. Second, discovery phase studies use the predominant retrospective
samples (Zhang & Chan, 2005).
The followings are the direct implications of these two biological facts:
•

Complexity of clinical specimen proteome: Human proteomes are complex
and dynamic. It is important to develop techniques that are less complex
and with narrower dynamic ranges.

•

Biological variability: Samples from different populations are significant.
The disease-associated proteomic expression data could be significantly
different from other expression data.

•

Preanalytical variability: There is insufficient protein information for
diseases. Proteins samples are often collected under different protocols.
The sample handling and processing may be different for the disease and
samples.
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•

Analytical variability: Minimization of analytical procedures variability is
necessary (Zhang & Chan, 2005).

There are also several difficulties due to technical challenges:
•

The lack of sensitivity and specificity of detecting low abundant biomarkers
and complex biological samples (Rai & Chan, 2006).

•

Limited detection technology of genome fraction (Alaiya et al., 2000).

2.5

Metabolomics

Metabolomics is the global quantitative study of metabolites using omics
technologies that utilizes the analytical instrumentation with pattern recognition
techniques to investigate changes in metabolites. Metabolomic profiling is
capable of detecting and quantifying metabolites in tissues and biofluids that are
associated with biological pathways (Beger, 2013). Metabolomics also has been
employed in discovery of functions of genes and proteins. Findings of
metabolomics provide insights into biological processes (Patti, Yanes, Siuzdak,
2012). Metabolites play important roles in cellular functions, including cell
signaling, energy transfer, and cell-to-cell interaction (Niedbala et al., 2009).
Metabolite profiles can be important markers of physiological and pathological
states. Analysis of metabolites has the potential to solve the questions on the
mechanism of disease occurrence and progression (Zhang & Du, 2012).
Metabolomics measures and monitors changes of small molecules that
are up- or down regulated by cell processes (Niedbala et al., 2009).
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Metabolomics in cancer research plays a critical role in understanding glycolysis
of tumor cells, which is called the “Warburg Effect”, production of the amino acids,
nucleotides and lipids that are required for tumor proliferation and vascularization
by recognizing the patterns of metabolites. The clinical goal of metabolomics is to
discover cancer biomarkers that are used for diagnosis and prognosis. Applying
various analytical techniques, metabolomics is able to correlate metabolites and
biological pathways in order to identify more accurate potential biomarkers
(Beger, 2013). This research study applied mass spectrometry in cancer
metabolomics. Using mass spectrometry in metabolomics, thousands of
metabolites can be rapidly measured with only minimal amount of samples (Patti,
Yanes, & Siuzdak, 2012).
Metabolomic analysis using mass spectrometry has four main steps.
Firstly, tumor samples are collected and extraction is performed on the biological
sample to harvest metabolites. Secondly, data is acquired by mass spectrometry.
Thirdly, bioinformatics tools are used to analyze the data (Beger, 2013). Current
metabolomics software, such as XCMS, does not output metabolite
identifications. These bioinformatics tools provide p-values and fold changes in
intensity between samples. After organizing the metabolites data using
bioinformatics tools, this data is compared with existing metabolites databases:
Human Metabolome Database and METLIN. A database match shows a putative
metabolite assignment. This result should be confirmed with retention time and
MS/MS data of the samples. However, a database match does not show a fair
number of metabolites that were detected by mass spectrometry (Patti, Yanes, &
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Siuzdak, 2012). The last step of metabolomics analysis is data interpretation
(Beger, 2013). The peaks that are shown in data are metabolite features and
correspond to a detected ion with a unique mass-to-charge ratio and a retention
time. Although metabolomic tools have been improved, there are still limitations.
The masses of compounds that are detected in global analyses do not match the
masses in metabolite databases. There are still many metabolites that are
unknown (Patti, Yanes, & Siuzdak, 2012).

2.5.1 Cancer Metabolism
Cancer cells require genetic and epigenetic alterations to maintain tumor
proliferation and metastasis (Wolf, Agnihotri, & Guha, 2010). Alteration of
glycolytic metabolism is the most common biological process alteration in cancer
(Agnihotri et al., 2013). Cancer cells synthesize carbohydrates, fatty acids, amino
acids, and nucleotides for rapid proliferation (Beger, 2013) by aerobic glycolysis
rather than mitochondrial oxidative phosphorylation (OXPHOS) and tricarboxylic
acid (TCA) cycle, which is called the Warburg Effect. Figure 2.3 describes
metabolic differences between normal and cancer cells. Normal cells produce
pyruvate from glucose and go through the TCA cycle and the OXPHOS process
with presence of oxygen to generate 36 ATPs per glucose. However, cancer
cells convert most glucose to lactate despite the presence of oxygen and
generate two ATPs per glucose. This anabolic process promotes rapid tumor
proliferation (Marie & Shinjo, 2011). Glycolysis is a biochemical process that
hydrolyzes glucose and produces two adenosine triphosphate (ATP), two NADH,
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and two pyruvate (Berger et al., 2004). Tumors generate more than 50% of ATP
by glycolysis even with the presence of oxygen. This is called aerobic glycolysis.
As a result of aerobic glycolysis, an increased level of lactate that is produced
from pyruvate in order to survive in microenvironment (Wolf et al., 2010). High
level of lactate requires the activation of biological systems that equilibrate the
intracellular pH level and may promote acidification of the tumor
microenvironment (Santos & Schulze, 2012). In cancer environment, pyruvate
dehydrogenase (PDH) activity is inhibited by pyruvate dehydrogenase kinase 1
(PDK1), a hypoxia-driven enzyme, and lactate dehydrogenase A (LHDA) activity
is upregulated. Elaborated level of lactate causes acidic tumor environment and
promotes tumor invasion (Marie & Shinjo, 2011).
GBM uses glycolysis and glutaminolysis to provide metabolic
macromolecules for the cell proliferation. In GBM in vitro, 90% of glucose and 60%
of glutamine produce lactate or alanine. GBM cells take advantage of this
method to increase the cell division velocity by carbon incorporation into biomass.
Glytaminolysis produces energy required for fatty acid synthesis by NADPH
production (Marie & Shinjo, 2011). Grade three and four brain tumors often show
alterations in phophoinositide 3-kinase (PI3K), EGF receptors (EGFR), vascular
epithelial growth factor (VEGF), and PTEN signaling. According to the Cancer
Genome Atlas Research Network, whole genome sequencing proved that
abnormal signaling through the RTK/RAS/PI3K, p53, and retinoblastoma (RB)
pathways play a critical role in glioblastoma development (Chinnaiyan et al.,
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2012). Over-expressed metabolites in GBM include 2-hydroxyglutarate and
isocitrate dyhydrogenase 1 mutation ( Patti, Yanes, & Siuzdak, 2012).

Figure 2.3. Metabolic differences between normal and cancer cells (Marie &
Shinjo, 2011).
2.6

Lipidomics

Lipidomics is the systems-level analysis that identifies and quantifies
pathways and networks of cellular lipids species. Lipidomics uses novel
analytical technologies to understand the classes of lipids, changes in lipid
metabolism and lipid-mediated signaling pathways, and interactions with other
lipids, proteins, and other molecules (Wang et al., 2009; Tripathy, 2011). Lipids
include fats, waxes, sterols, fat-soluble vitamins, monoglycerides, diglycerides
and phospholipids.
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There are two main techniques that are utilized to analyze lipids species
and interactions: liquid chromatography and mass spectrometry (MS) (Tripathy,
2011). This research study focuses on analysis of lipids using mass spectrometry,
which is most frequently used in lipidomic research. Mass spectrometry in
lipidomics provides higher quantitation performance and higher sensitivity than
other exiting techniques. There are three main MS techniques, which are global
lipidomic analysis, targeted lipidomic analysis, and novel lipid discovery. Global
lipidomic analysis identifies and quantifies different types of lipids through a high
throughput basis. This technique is used to analyze various pathways and lipid
metabolism, trafficking, and homeostasis. Mapping techniques are used to
investigate the spatial and temporal associations of lipids. Targeted lipidomics
analysis is utilized to identify few specific lipid classes. Novel lipid discovery
focuses on the discovery of novel lipid classes and molecular species (Tripathy,
2011)

2.6.1 Cancer Lipid Metabolism
Most lipids exist in cell membranes comprising the lipid bilayer. Due to the
membrane organizing properties of lipids, lipids play many important roles in a
cell, tissue and organ physiology. The main biological functions of lipids are as
energy storage, structural components of cellular membranes, changes in cell
membrane composition, cell signaling, endocrine actions, membrane trafficking,
regulating membrane proteins, systemic lipid metabolism, lipid oxidation, and
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biochemical reactions in the cells (Tripathy, 2011). Lipids are also co-sorted with
proteins during the formation of transport carriers (Shevchenko & Simons, 2010).
Brain tissue contains the highest amount of lipids compared to other organs.
Human brain consists of 5-15% lipids, 70-83% water, and 7.5-8.5% proteins. The
most abundant lipids are classified as cholesterol, phospholipids, and
sphingolipids. White matter contains 27% cholesterol and 45% phospholipids,
and gray matter contains 20% cholesterol and 67% phospholipids. When
glioblastoma tumors are formed in the brain, lipid content decreases.
(Campanella, 1992).
Lipid metabolism in cancer environment is regulated by oncogenic
signaling pathways, and plays an important role in cancer initiation and
progression (Zhang & Du, 2012). Lipid metabolism alteration may impact
membrane structure, synthesis and degradation of lipids, homeostasis, and
signaling functions. Lipid studies in cancer provide evidence that altered lipid
metabolism supports tumor proliferation, differentiation, and motility (Santos &
Schulze, 2012). Malignant transformation changes biosynthetic and bioenergetic
tumor environments (Zhang & Du, 2012). Currently, most cancer lipid metabolism
research studies focus on the increased level of fatty acid synthesis in the tumor
environment. Figure 2.4 describes function of fatty acids stimulated by oncogenic
signaling (Santos & Schulze, 2012). Enzymes that are involved in fatty acid
synthesis, such as ATP citrate lyase (ACL), acetyl-CoA carboxylase (ACC) and
fatty acid synthase (FASN), are often over-expressed in many cancer types. Free
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fatty acid levels are higher in more aggressive cancer cell lines and high-grade
primary tumors.

Figure 2.4. Functions of fatty acids in cancer cells (Santos & Schulze, 2012).
Alternation of lipid metabolism affects the phenotype of cancer cells. Large
amount of lipids are required for forming the cell membrane when cancer cells
proliferate (Santos & Schulze, 2012). Cancer cells rely on de novo endogenous
lipid synthesis rather than exogenous dietary lipid synthesis. De novo lipogenesis
has many important roles in tumor formation, such as membrane formation, lipid
molecule signaling, protein modifications, and energy supply for rapid tumor
proliferation. Fatty acids that are endogenously produced are often esterified to
phospholipids to meet the needs of tumor formation, including structural building
blocks, formation of a detergent-resistant membrane microdomain for tumor
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signal transduction, polarization, intracellular trafficking, and migration of the
cancer cells. Lipid molecules that mediate signal transduction, such as
phosphatidic acid (PA), diacyl-glycerol (DAG), and lysophosphatidic acid (LPA),
can activate signaling proteins or bind to G protein-coupled receptors (GPCRs) in
order to control tumor proliferation, survival, and migration. Fatty acid can also go
through β-oxidation to provide energy for cancer cells. In Akt-overexpressing
glioblastoma, fatty acid oxidation is sufficient to support tumor cells and prevent
glucose withdrawal-induced death (Zhang & Du, 2012).
Cancer cells frequently exist in hypoxic regions. GBM tumors are
heterogeneous with pseudopalisading perinecrotic cells in modedate hypoxic
region (pO2 = 2.5-5%) and infiltrating cancer cells in normal brain oxygen
conditions (pO2 = 10%) (Wolf et al., 2010). When the oxygen level is low,
hypoxia-inducible factors (HIFs) are activated. With alternations in Von HippelLindau (VHL) tumor suppressor, HIF1-α and HIF2-α are stabilized even in
presence of oxygen. Activation of HIFs may also occur by oncogenic pathways
and deletion of p53. HIFs play many important roles in tumor growth process.
Activated HIF upregulates vascular endothelial growth factor and encourages
angiogenesis. It also promotes tumor cells to stabilize in hypoxic environment by
anaerobic energy production. HIF1 upregulates the expression of FASN. HIF1
induces the hypoxia-inducible protein 2, a protein playing a role in deposition of
neutral lipids into lipid droplets, in order to accelerate the accumulation of lipids. It
also induces the peroxisome proliferator-activated receptor γ to support free fatty
acid uptake and triacylglycerol production in liver and adipose tissue. In hypoxic
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environments, glutamine plays an important role in lipid synthesis by providing
carbon without mitochondrial activity (Santos & Schulze, 2012).
Lipid profiles are powerful information for drug and biomarker
development. Lipid metabolism is potentially used as evidence of the
identification of pathways. Analysis of lipids with other omics studies will provide
better understanding of diseases that involve disruption of lipid metabolic
enzymes and pathways (Tripathy, 2011).

2.6.2 Limitations
Lipidomic analysis has been difficult due to the specificity and complexity
of lipid composition and the lack of techniques for the analysis (Tripathy, 2011).
Regulation and the mechanisms of lipid compositional complexity associated with
cell homeostasis are still poorly understood (Shevchenko & Simons, 2010).
Moreover, mass spectrometry has limitations in the structural identification of
lipids. Due to various classes and molecular species of lipids, it is extremely
difficult to accommodate all lipid classes using existing current detection methods.
In contrast to genomics and proteomics, current lipidomics technologies are not
capable of predicting the number of individual lipid molecules in an organism.
Therefore, mapping lipidomes is still unattainable using existing technologies
(Tripathy, 2011). As a result of the lack of lipidome information, genomic and
proteomic profiles have not been matched with knowledge of lipids. Despite the
fact that identification of protein-lipid interactions is increasing, the structural
mechanisms of a cell remain unclear (Shevchenko & Simons, 2010).
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2.7

Summary

This chapter has provided an overview to the review of relevant literature.
It provided information of glioblastoma, existing treatment options, advantages
and disadvantages of the animal models, proteomics, metabolomics, and
lipidomics in GBM studies. This chapter confirms that cancer model development
and discovery of novel targeted therapy are desperately needed.
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CHAPTER 3. METHODOLOGY

This study was conducted in order to identify significantly expressed lipids
and correlate patterns of cancer metabolism that can be compared to
glioblastoma metabolites and proteins. The workflow of lipidomics contained two
main parts: biological sample preparation and data analysis (Figure 3.1).
Biological sample preparation contains harvest and collection of GBM xenograft
tumor (Figure 3.1-1A-B), and lipid extraction from the tumors (Figure 3.1-1C).
The lipid fraction was taken and run through RHPLC (Figure 3.1-1D) frontcoupled to Bruker 7T Mass Spectrometer in ESI-FTMS mode (Figure 3.1-1E).
Data analysis contains raw MS data conversion into a compatible format (Figure
3.1-2A), data processing performed in mzMINE (Figure 3.1-2B), statistical
analysis (Figure 3.1-2C), LIPID MAPS database search of top 30 most significant
lipids (Figure 3.1-2D), and hierarchical clustering of the data (Figure 3.1-2E).
This chapter outlines the details of human GBM cell line information,
xenograft models, biological sample extraction, the instrument, and data analysis
tools.
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Figure 3.1. Overview of lipidomic analysis of GBM workflow.
3.1

Cell Lines and Cell Culture

Primary human GBM cell line GBM10 and GBM43 were surgically
removed and provided from the Mayo Clinic, Rochester, Minnesota. Both cell
lines were known to be resistant to temozolomide and several molecular
properties were tested prior to this experiment. GBM10 and GBM43 both
expressed normal EGFR and PTEN. GBM10 also has wild-type p53, tumor
suppressor gene that is involved in many biological functions, yet GBM43 has
mutant p53 (Carlson et al., 2011). Two types of in vivo mouse xenograft models
(orthotopic and subcutaneous) of glioblastoma were needed and maintained at
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the Indiana University School of Medicine. GBM10 and GBM43, which are
resistant to current therapeutic options and actively investigated by the Brain
Tumor Working Group of IUSM clinicians and science investigators from Purdue
University, were propagated in the cerebrum of NOD/SCID mice. These cell lines
were expanded in in vitro environment for approximately two to three weeks
before being injected into the mouse xenograft models. 3x106 cells were injected
into right cerebral hemisphere and flank site of mice. Five mouse models were
utilized per GBM cell type. Figure 3.2 summarizes the biological sample
preparation process from in vitro cell expansion to protein, metabolite, and lipid
extraction.

Figure 3.2. Overview of biological sample preparation process for mass
spectrometry.
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3.2

Mouse Orthotopic Models

NOD/Scid mice were obtained from the onsite breeding colony in the In
Vivo Therapeutics Core at the Indiana University School of Medicine. All studies
were reviewed and approved by the Indiana University Animal Care and Use
Committee. GBM10 and GBM43 cells were implanted in the right flank in matrigel
at 3 x 106 cells per mouse. For intracranial implantation, a digitalized stereotaxic
delivery system was utilized (David Kopf Instruments, Model 5000 microinjection
unit, Tujunga, CA). REF-1,2 for stereotaxic delivery of tumor cells, mice were
placed under general anesthesia (ip injection of 16 mg/kg xylazine and 150
mg/kg ketamine) and positioned in the stereotaxic device. A digitalized drill
assembly was used to bore a hole 0.3–mm in depth and 0.8-mm diameter in the
cranium at a position 0.5-mm anterior and 1.2-mm lateral to the bregmal
anatomical landmark. Tumor cells (2 x 105 in 10 ml of RPMI medium) were
introduced slowly using a 10 ml Hamilton syringe at a depth of 3.5 mm at a rate
of 2 µl/min. Once injection was complete, the needle was kept in place for at
least 5 minutes and then slowly removed and the hole sealed with bone wax. The
incision was closed with a wound clip. These models have been validated in past
studies and the median survival is 21 to 24 days post-implantation of tumor cells.
Figure 3.3 shows in vivo detection of orthotopic primary GBM10 tumors at week
three and four by bioluminescent imaging. Mice with flank tumors were
euthanized once tumors reached ~250 mm3.
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Figure 3.3. In vivo detection of orthotopic primary GBM10 by bioluminescent
imaging.
Tumors were excised, flash frozen, and stored at -80oC. For mice with
intracranial tumors, the mice were observed daily starting at 2 weeks and prior to
reaching the pre-death endpoint were euthanized. Tumor tissue was excised
from the right cerebrum and flash frozen and stored at -80oC. Twenty-eight tissue
samples of GBM10, GBM43 from brain and flank site, and control brains from
total ten mouse models were listed in Table 3.1 & 3.2.
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Table 3.1.
Quantity of tissue samples harvested from GBM xenograft models.
Cell line
GBM10

GBM43

Tissue type

Amount

Brain tumor

5

Flank tumor

5

Control

5

Brain tumor

5

Flank tumor

4

Control

5

Table 3.2.
Mouse xenograft tumor sample information.
Sample

Mouse ID

Cell Type

Tumor/Tissue Site

1

1

GBM10

Brain

2

1

GBM10

Flank

3

1

Control

Brain

4

2

GBM10

Brain

5

2

GBM10

Flank

6

2

Control

Brain

7

3

GBM10

Brain

8

3

GBM10

Flank

9

3

Control

Brain

10

4

GBM10

Brain

11

4

GBM10

Flank

12

4

Control

Brain

13

5

GBM10

Brain

14

5

GBM10

Flank

15

5

Control

Brain

16

M-1

Control

Brain
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Table 3.2 (continued).
Mouse xenograft tumor sample information.
Sample

Mouse ID

Cell type

Tumor/Tissue site

17

M-1

GBM43

Brain

18

M-1

GBM43

Flank

19

M-2

Control

Brain

20

M-2

GBM43

Brain

21

M-2

GBM43

Flank

22

M-3

Control

Brain

23

M-3

GBM43

Brain

24

M-4

Control

Brain

25

M-4

GBM43

Brain

26

M-4

GBM43

Flank

27

M-5

Control

Brain

28

M-5

GBM43

Brain

29

M-5

GBM43

Flank

3.3

Protein, Metabolite and Lipid Extraction

Sample preparation of the mouse tumors prior to mass spectrometry was
performed using a novel biomolecule extraction method to harvest the proteins,
metabolites, and lipids in one simple and fast procedure.
10mg to 100mg of in vivo mouse GBM tumor tissues were placed in a low
retention 2.0ml microcentrifuge tube and placed on ice. These tumor samples
were mixed with 200µl of 75% MetOH in 0.15M NaCl. Approximately 50µl of
grinding balls (ZrO; diameter ~0.5 mm) were added to each tube in order to
homogenize the tumor tissues using a Next Advance Bullet Blender for two
minutes. This step was repeated until the tissues were completely homogenized.
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After the tissue homogenization, 20µl of suspension from each tube was
transferred into the new 1.5ml microcentrifuge tubes. The homogenized samples
were mixed with 180µl of 0.15M NaCl and 1ml of chloroform/methanol (2:1) with
0.01% BHT by vortex for two minutes, then incubated in room temperature for 30
minutes. After the incubation, the tubes were centrifuged for five minutes at
7,800xg. 250µl of the lower chloroform phase of the mixtures were transferred
into the new tubes and labeled as ‘lipid’ fraction. These lipid fractions were stored
in -80°C until mass spectrometry was performed. Remaining lipid phase of the
samples were discarded and briefly vortexed. 100ul of suspension of each
sample was transferred to the new microcentrifuge tubes. These suspensions in
the new tubes were mixed with 100µl of MetOH, vortexed, and centrifuged for
five minutes at maximum speed. The supernatant was transferred to the new
tubes and labeled as ‘Polar Metabolites’ fraction. These polar metabolite
fractions were also stored in -80°C. The pellets were washed with cold acetone
by resuspending and centrifuging. After discarding acetone, the pellets were
resuspended with the buffer. These mixtures were the ‘protein’ fraction.
For aniline labeling of polar metabolite fraction, the samples were dried under
nitrogen. Then, dried samples were resuspended in 100µl of 0.15M NaCl.

3.4

Instrument

Mass spectrometry with front-end, reverse phase high-performance liquid
chromatography (RHPLC) for molecule separation was performed on the sample
fractions using electrospray ionization Fourier transform mass spectrometry (ESI-
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FTMS; 7 T Bruker Instrument). The 26 lipid samples were randomly ordered and
assigned corresponding designations. Thirty microliters of each sample were
loaded into the appropriate vials and placed in the auto-sampling tray of an
Agilent 1200 series HPLC running in the reverse phase with an ACE C8 silica
column. The column utilized a solvent gradient as described in Table 3.3. The
auto-sampler loaded 2 µl from each vial, running a methanol blank both prior to
sampling and twice after each sample to ensure full elution of the sample from
the column. After elution, each sample ran directly to the mass spectrometer.
Electrospray ionization (ESI) reduces risk of fragmentation of the lipid during
ionization. Meanwhile, FTMS provides high mass resolving power relative to
other modes of mass spectrometry, allowing for enhanced detection of unique
lipids. The mass spectrometer was run in both positive-ion mode and negativeion mode to ensure a complete profile of lipids was achieved.

Table 3.3.
HPLC gradient parameters for lipid separation in reverse phase using Solvent A
as 0.1 % formic Acid, 10 mM ammonium acetate in water and Solvent B as 0.1%
Formic Acid, 10 mM ammonium acetate in acetonitrile: asoproponol in a 1:1 ratio.
Time (minutes) % Solvent A % Solvent B
0

70

30

1

70

30

25

0

100

45

0

100

47

70

30

60

70

30
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3.5

Data Analysis

Profile data from the mass spectrometry was in the form of peak areas for
each for recognized masses, which were converted to XML format and imported
in the open source pre-processing software mzMine2. mzMine2 is a data
processing tool for LC-MS data and designed for metabolomics profiles. This tool
was utilized for peak detection, shoulder filtering, isotope removal, and gap filling
(Pluskal et al., 2010) to compare control brain tissue to brain tumor tissue and
flank tissue for the GBM10 and GBM43 samples independently. A series of
homoscedastic t-tests comparing GBM10 and GBM43 brain, flank, and control
tumors in all possible permutations identified the most significantly differentially
regulated lipids. A selection of these were identified using LIPID MAPS, a webbased lipid database, which uses a text/ontology – based search to identify sub
class, class, and common structure of a lipid within a variable m/z tolerance of
0.1-5 m/z.

3.6

Summary

This chapter has provided an overview to methodology of the research
project, including the sample harvest, biomolecule extraction, maintenance and
collection of data, and introduction of analysis tools.
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CHAPTER 4. PRESENTATION OF THE DATA AND FINDINGS

The methodology of this project was performed to answer the research
questions as introduced in Chapter 1. These questions were (1) what are the
similarities and differences of molecular profiles between brain (orthotopic) and
flank (subcutaneous) tumors in mouse xenograft model; and (2) are there
biomarkers in GBM10 and GBM43 that are related to metabolic properties of
GBM?
This chapter presents the mass spectrometry data that was processed
with various bioinformatic and statistical tools, and the list of identified lipid
classes. It also provides the comparison data between two different GBM cell
lines and two different xenograft models. Detail interpretation of these results and
further observations are described in Chapter 5.

4.1

Mass Spectrometry Data

Among all 26 samples, 11218 unique positive-ion mode peaks were
quantified by mzMine2, representing an m/z ratio range of 244 to 1,800. To filter
out insignificant peaks, a truncated data set was created by removing any peak
detected in fewer than five samples, as there were five replicate samples in each
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model grouping. This yielded 4,422 positive-ion mode peaks. A similar process
for data ran in the negative-ion mode yielded 725 unique peaks.
Of the positive-ion mode data, 368 lipids were identified to be significantly
different in lipid levels between GBM10 brain tumor tissue and the control tissue,
305 between GBM43 brain tumor tissue and the control tissue, and 1960 lipids
between all brain tissue (both GBM10 and GBM43) and all flank tumor tissue. Of
the negative-ion mode data, 149 lipids were significantly expressed between
GBM10 brain tissue and the control tissue, 233 between GBM43 brain tissue and
the control tissue, and 211 lipids between all brain tissue and all flank tissue.
Summary of the number of significant lipids from different tissue types and the
ratio of significantly decreased and increased lipids compare to control is shown
in Table 4.1. More than 500 lipid species were significantly detected per different
tissue type. More than 90% of these lipids were decreasingly expressed in both
GBM10 and GBM43. This data clearly reported that GBM tumor tissue contains
dramatically lower levels of lipid composition than normal brain tissue.

Table 4.1.
Differentially expressed significant lipids in different types of GBM tissues
compare to control brain tissues.

Positive ion
mode
Negative ion
mode

GBM43
Brain
21
284 (93.1%)

GBM10 Flank

Over-expressed
Under-expressed

GBM10
Brain
26
342 (92.9%)

Over-expressed
Under-expressed

2
147 (98.7%)

0
233 (100%)

4
153 (97.5%)

360
1566 (81.3%)
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4.2

Significantly Expressed Lipids in GBM

Since there were over 500 identified lipids from different tissue types, the
30 most significantly identified lipids from each tissue type, which have p-value
less than 0.05 and fold effect intensity greater than one, were plotted in order to
visualize the most differentially expressed lipid classes, which are
glycerophosphocholines, glycosphingolipids, glycerophosphoethanolamines,
triradylglycerols, and glycerophosphoserines (Figure 4.1). The x-axis of the graph
represents the structures of significantly identified lipids and the y-axis shows the
fold effect change intensity of the lipids compare to control.
The positive ion profiles of glycosphingolipids showed similar lipid
distribution between GBM10 and GBM43 brain tumors. Both types of brain
tumors showed decreased level of glycosphingolipids. No flank tumor lipids were
observed on the positive ion plot. However, the negative ion profiles did not show
any lipids of GBM43, yet did show GBM10 and flank tumors (Figure 4.1 A).
Mostly under-expressed flank tumor lipids were observed from the positive ion
profiles. On the other hand, identified lipids from the negative ion profiles were
equally distributed, mostly showing decreased level of lipids, among GBM10
brain tumors, GBM43 brain tumors, and all flank tumors. Most significantly
identified lipids of the negative ion profiles among different tissue types were
identified as glycerophosphocholines (Figure 4.1 B). Among the significant lipid
classes, glycerohposphoserines were over-expressed throughout all different
tissue types. GBM43 showed the highest fold effect change among all different
tissue types, which is distinct since no fold effect of brain tumor lipids was
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expressed higher than flank tumor. The negative ion data only showed the lipids
from GBM43 and the flank tumors (Figure 4.1 C). The triradylglycerol plot
showed equally distributed lipids from different tissue types. Some lipids of
GBM10 and flank tumor were increased, yet majority levels of lipids were
decreased (Figure 4.1 D). Apart from this distinction, casual observance implied
that the flank tumor lipid profiles showed greater fold change intensity compare to
the brain tumor profiles.

4.3

Orthotopic and Subcutaneous Xenograft Tumors

Significantly identified lipids between brain tumor tissues and flank tumor
tissues were compared to investigate the similarities and differences. Table 4.2
represents the number of identified lipids in flank tumor compared to brain tumor
tissues. There were a total of 1,960 significantly regulated positive ion lipids and
206 negative ion lipids in brain tumors compared to flank tumors. As the table
shows, the majority of significant lipids were decreased in flank tumor tissues.
Differentially expressed lipids between brain and flank tumors supports the
pattern on Figure 4.1 and 4.2, which expresses m/z range and different fold
effect change among the brain tumors and the flank tumors. Generally, lipidomic
profiles of the flank tumors exhibit higher fold effect intensity than the brain
tumors.
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Figure 4.1. Top 30 significantly expressed lipid structures and lipid classes
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Table 4.2.
Differentially expressed significant lipids between brain tumors and flank tumors.
Number of lipids
Positive ion mode
Negative ion mode
Over-expressed

267

7

Under-expressed

1693

199

GBM 10 Brain, GBM 43 Brain, and Flank vs.
Control Comparison
16!
14!
12!

Fold Effect

10!
8!
6!
4!
2!
0!
"2!

0!

200!

400!

600!

800!

1000!

1200!

1400!

1600!

1800!

"4!
"6!

m/z Ratio
GBM 10 Brain Tumors

GBM 43 Brain Tumors

Flank Tumors, ALL

Figure 4.2. m/z and fold effect comparison of each tissue type.
4.4

Hierarchical Clustering of GBM Tumors

For quality assurance purposes, a series of statistical approaches were
employed in order to identify any definite peculiarities with the results. In
particular, a chief focus was to determine whether the data for the samples
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demonstrated affinities consistent with the grouping of the samples. For this
purpose, a set of clustering algorithms, Divisive ANAlysis (DIANA) and
AGglomerative NESting Hierarchical Clustering (AGNES), were performed. To
generate the clusters of the samples, m/z values and peak intensities from
MzMine2 data were compared. As a result, the output from DIANA and AGNES
showed similar patterns of clusters while these two algorithms have distinctly
different paths to generate the output (Kaufman & Rousseeuw, 2009) and have a
history of use with similar data (Gough et al., 2008).
As is evident from Figures 4.3 – 4.6, these disparate approaches
produced closely related results. All the figures generated from DIANA and
AGNES showed a propensity for the flank subjects to clearly cluster away from
the other tissue types while the brain and control groups demonstrate a more
closely clustered set of results. However, even in the brain and control groups,
each group tended to segregate in the expected cohorts.
Based on the evidence rendered from using DIANA and AGNES, it is
likely that the results achieve the aforementioned affinities, and accordingly the
pattern mining efforts help to establish the viability of the experimental protocol.
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Figure 4.3. DIANA output from positive mode data.

Figure 4.4. AGNES output from positive mode data.
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Figure 4.5. DIANA output from negative mode data.

Figure 4.6. AGNES output from negative mode data.
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4.5

Summary

This chapter has presented the data from mass spectrometry and various
approaches to discover significance of the data. Employing bioinformatic tools
and statistical tests identified significantly expressed lipids from different tissue
types. Hierarchical clustering methods were also utilized to validate the data
analysis approaches.
The next chapter draws upon the data presented in this chapter in order to
define conclusions and discussion of the methods and results.
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CHAPTER 5. DISCUSSION, CONCLUSIONS, AND RECOMMENDATIONS

This chapter discusses the results generated by lipidomics workflow and
mentions any observations that may affect the outcome of the experiment. It also
summarizes the overall findings of this study and present potential future work to
support the hypotheses that were drawn.

5.1

Discussion

5.1.1 GBM Cell Lines and Tumor Sizes
In vivo xenograft models were utilized to expand GBM tumor formation for
the biomolecule extraction since cell viability and growth rate of GBM10 and
GBM43, known to be resistant to temozolomide, were not consistently stable
after approximately two to three weeks in in vitro environment. GBM cells were
incubated in mouse xenograft models from 21 to 24 days in order to harvest
appropriate size of tumors from viable mouse condition. Figure 5.1 represents
the tumor sizes due to the different tissue types. The box plot of the tumor size
showed that the size of GBM43 flank tumors was significantly smaller compared
to other tumor tissues. GBM43 did not appeared on one of the mouse models so
that only four GBM43 flank tumors were harvested instead of five. Moreover,
three out of four GBM43 flank tumors were too small (1mg, 2mg and 2mg) for the
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biomolecule extraction, which was designed for the tissue mass between 10mg
and 100mg. Morphological differences between different GBM cell lines might be
related to the tumor formation characteristics in xenograft models since GBM10
tends to form more localized tumors and GBM43 is known to have more invasive
properties compare to GBM10.
Biomolecule extraction procedure also showed histological differences
between GBM10 and GBM43. Flank tumor tissues were more difficult to
homogenize compared to brain tumors and control samples. Control brain and
brain tumor tissues were mostly homogenized on the first attempt. However,
most of the flank tumors from GBM10 and GBM43 were homogenized up to five
times in order to break down the tissue.

GBM Tumor Size
Tissue mass (mg)

120
100
80
60
40
20
0
GBM 10
Brain T

GBM 43
Brain T

GBM 10
Flank T

GBM 43
Flank T

GBM 10
Control

GBM 43
Control

Tissue type

Figure 5.1. Tumor size comparison between different GBM tumors and control.
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5.1.2 Biological Sample Preparation for Mass Spectrometry
The protocol for protein, metabolite, and lipid extraction was designed for
the tissue size between 10mg and 100mg. This protocol was designed to
overcome current limitations of sample preparation of metabolites and lipids.
The extraction method was developed to extract proteins, metabolites, and lipids
from one sample preparation. This method can be beneficial for the sample
preparation in several ways. First, simple and minimal procedures can save
sample preparation time, minimize degradation of metabolites, and lower sample
loss during preparation period. Second, the samples from this protocol include a
wide range of metabolites and proteins, which is beneficial for untargeted omic
studies. Third, due to the simple and fast sample preparation steps, the sample
preparation is easily reproducible. Reproducibility is important in omic studies,
which use a large number of samples (Vuckovic, 2012).

5.1.3 Data Analysis
Quantitative analysis of the significantly differentially regulated lipids
establishes patterns which indicate noteworthy differences between orthotopic
and xenographic models of glioblastoma in mice. As previously mentioned,
cursory analysis using t-tests and manual identification indicated that while
general lipid profiles of flank tumors and brain tumors appeared to be in similar
m/z range, comparison of lipid classes showed different lipid contents between
different tissue types. Statistical validation method, hierarchical clustering,
indicates distinct profiles of lipids in flank tumor tissues distinguished from both

59
brain tumor and brain control tissue, as brain tumor and brain control tissue
cluster together. This evidence may suggest that brain tumors and control tissues
were more similar to each other than flank tumor tissues. The clustering output
may also imply that certain ‘background noise’ from surrounding tissue of the
tumor (i.e. the variance in lipid composition of brain tissue and flank tissue) can
account for a small portion of this clustering pattern.
Beyond the hierarchical clustering of the data, lipid identification
introduces an element of uncertainty into the analysis. Because the mass
spectrometer returned hundreds of significantly differentially regulated lipids,
many of which shared nearly identical m/z ratios, power of manual analysis is
influenced by both (1) the resolution of the LipidMaps database and (2) the size
of the database (containing just over 37,500 unique lipids). The potential of
fragmentation and creation of adducts within the ion generator, though roughly
accounted for by mzMine2, adds further complication in manual identification of
lipids. The instrument used, a Bruker 7-Tesla FT-MS, utilizing the solariX
platform, provides mass accuracy on the magnitude of greater than under one
part per million, which greatly increases the certainty of database returns on lipid
identification. Likewise, the soft-ionization of the electrospray limits fragmentation
and is compatible with front-coupled RHPLC used to separate lipids prior to
analysis in the spectrometer.
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5.2

Biological Implications

5.2.1 Lipid Studies and Decreased Level of Lipids in GBM
Our data showed that more than 90% of significantly identified lipids from
in vivo brain and flank GBM tumors were under-expressed compared to the
control brain tissue. On the other hand, the majority of the studies in cancer lipid
metabolism have a tendency to focus on increased level of fatty acid synthesis
(Zhang & Du, 2012). Lipidomic analysis has been difficult due to the specificity
and complexity of lipid composition and the lack of techniques for the analysis
(Tripathy, 2011). Regulation and the mechanisms of lipid compositional
complexity associated with cell homeostasis are still poorly understood
(Shevchenko & Simons, 2010). Moreover, mass spectrometry has limitations of
the structural identification of lipids. Due to various classes and molecular
species of lipids, it is extremely difficult to accommodate all lipid classes using
existing current detection methods (Tripathy, 2011). Due to these difficulties in
lipid studies, many research projects investigated the protein level of tumors to
study lipid metabolism and not actual composition of lipids in cancer cells.
However, few number of lipid studies in gliomas examined the correlation
between membrane lipid composition and malignancy of astrocytomas. A study
that was published in 1992 measured membrane lipid changes among different
grades of human gliomas using HPTLC. This study concluded that higher level of
malignant glioma has significantly lower level of total plasma membrane lipids in
tumor tissues (Campanella, 1992). More recent study using mass spectrometry
to classify types of gliomas also showed that the profile of grade IV astrocytoma
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total lipid abundance were lower than the low-grade astrocytomas (Eberlin et al.,
2012).
Aggressive and high-grade primary cancer cells tend to have higher level
of free fatty acid/ lipid droplets compared to normal or lower grade tumors.
Monoacylgylcerol lipase (MAGL), a lipolytic enzyme that breaks down
monoacylglycerols (MAGs) to produce glycerol and a free fatty acid, are also
highly up regulated in aggressive form of cancer cells. Inhibition of MAGL
showed that migration, invasion, and survival characteristics of cancer cells were
inhibited in vitro and in vivo models (Zhang & Du, 2012). However, the
mechanism of lipid droplets in cancer cell proliferation and survival is not well
understood (Santos & Schulze, 2012). Our preliminary data of glioblastoma stem
cell showed that these stem cells did not show the metabolic patterns of the
Warburg Effect. If the cancer cell does not depend on glucose consumption, an
alternative bioenergy mechanism should be utilized to maintain tumor cell
survival (Liu, 2006).

5.2.2 Lipid Function and Fatty Acid Oxidation
Lipid functions in highly proliferating cancer cells are critical for building
membranes for the cells and high level of lipids are required. The Warburg Effect
explained that cancer cells utilize aerobic glycolysis rather than mitochondrial
oxidative phosphorylation (OXPHOS) and tricarboxylic acid (TCA) cycle to
maintain cancer environment (Tennant, Duran, & Gottlieb, 2010). According to
our glucose flux biosensor experiment of glioblastoma stem cells, GBM stem
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cells with rapid growth rate did not show significant amount of glucose utilization,
which contradicts the Warburg Effect. This result supports the hypothesis that
GBM may have a different cancer metabolism pattern other than the Warburg
Effect. There are some cancer types that do not utilize high levels of glucose as
cancer energy source. Prostate cancer does not depend on glucose for survival.
Instead, prostate cancer shows increased uptake of fatty acids and upregulated
beta-oxidation enzymes, which implies that prostate cancer cells depend heavily
on fatty acid oxidation to maintain proliferation of cancer (Liu, 2006). Fatty acid
oxidation also has a critical role in the proliferation and survival of leukemia
(Samudio, et al., 2010). Energy stress and high glucose uptake can lead to
increased fatty acid oxidation activity. In GBM, fatty acid oxidation contributes to
energy production and resistance to oxidative and nutrient stress (Santos and
Schulze, 2012).
There were few studies that examined the role of fatty acid oxidation in
GBM to investigate the significance of fatty acid and cancer survival. These
studies confirmed that stimulation of fatty aid oxidation provides sufficient energy
for GBM to maintain cell survival and protect the cells from glucose deprivation.
Moreover, more aggressive cancer cells lines expressed higher level of free fatty
acid (Buzzai et al., 2005). This evidence of aggressive GBM and fatty acid
oxidation can potentially explain the characteristics of GBM metabolism.
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5.2.3 Signaling Pathways and Lipid Metabolism
Our lipidomics data showed significantly lower level of lipids in GBM,
which does not support the cancer metabolism and signaling pathways. Figure
5.2 shows the signaling pathways that are related to lipid metabolism in cancer
environment with mutant p53.

Figure 5.2. Signaling pathways and regulation of lipid metabolism in cancer
According to these cancer signaling pathways with p53 mutation, lipid synthesis
level is upregulated in order to synthesis necessary lipids to maintain tumor
growth. Tumor suppressor gene, p53, is the gene that is most commonly
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alternated in many types of cancer and has various roles in metabolic regulations.
Approximately 50% of cancer has p53 gene mutations (Maddocks & Vousden,
2011). Because of that reason, many cancer research projects are investigating
mutation of p53 and alteration of metabolism in cancer. However, GBM shows
distinct patterns of p53 mutation and tumor malignancy. Tumor suppressor gene,
p53, mutations have been found in 25-30% of primary GBM and 60-70% in
secondary GBM tumor. On the other hand, approximately 50% of lower grade
glioma show p53 mutation, which explains that higher malignant forms of glioma
have a less alternated p53 gene (Wang et al., 2009).

5.3

Conclusions

GBM10 and GBM43 cell lines were able to form appropriate size of brain
tumor tissues with relatively healthy mice conditions. However, GBM43 tumors
from subcutaneous sites were either too small or did not appear. Decreased cell
growth and viability indicates that these cell lines may not be appropriate for
long-term in vitro culture environment.
Overall, brain and flank tumors in mouse xenograft models showed
decreased levels of lipids compare to control. Mass and charge ratio, m/z, ranges
of identified lipids were also similar. However, there were profile differences in
classes of significant lipids among these two xenograft tissues. Flank tumors also
showed higher fold effect compared to brain tumors. The homogenizing
procedure during the biomolecule extraction implied that histological
characteristics of the brain tumors and flanks tumors were different. Hierarchical
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clustering data analysis supported that control and brain tumor tissues were
more closed related to each other than flank tumor tissues.
Figure 5.2 presents the classical lipid metabolism pathways in cancer
environment with mutant p53, which does not match with the decreased lipid
level from our data. Many studies suggested that aggressive tumors contain
higher level of free fatty acids for energy source purpose. From this study, GBM
cells had significantly lower level of lipid contents compared to the normal brain
tissue. These results implied that GBM might use fatty acid oxidation as the main
energy source in nutrient deprived cancer environments.
Our results do not follow the mutant p53 and lipid metabolism pattern,
which is increased level of lipids. The lower percentage of p53 mutations in
primary GBM compared to lower grade of gliomas and relationship between wildtype p53 and lipid metabolism suggest a hypothesis that GBM might manipulate
biological functions of the wild-type p53 gene to metastasize and survive.

5.4

Future Recommendations

As mentioned in the Lipid Analysis section, we can compare the identified
significant lipids with known pathways of tumor genesis. We anticipate these
results will be supported by related metabolomic and proteomic data from the
same set of samples, especially concerning potential down-regulation of lipid
concentration in pathogenic tissue as a result of hypothesized oxidative lipid
metabolism in glioblastoma tumor cells. We hypothesize proteomic data will
return increased levels of enzymes implicated in both catabolism and anabolism
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of lipids, while metabolic data will confirm decreased frequency of glycolytic
pathways in favor of oxidative lipid metabolism.
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